Nadya J Jammal (Nadya Jammal)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Acute Myeloid Leukemia

Combination Therapy

Tyrosine Kinase

Top Venues

American journal of hematology

Expert opinion on emerging drugs

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

This page only lists publications with an associated author ORCID identifier.

Publications

Elias J Jabbour, Nicholas James Short, Nitin Jain, Nadya J Jammal, Jeffrey Jorgensen, Sa Wang, Xuemei Wang, Maro Ohanian DO, Yesid Alvarado, Tapan Mahendra Kadia, Koiji Sasaki, Rebecca Garris, Guillermo Garcia Manero, Farhad Ravandi, Hagop M Kantarjian
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 -4 and higher. American journal of hematology 97 (9) (2022)
Caitlin R Rausch, Courtney D D DiNardo, Abhishek Maiti, Nadya J Jammal, Tapan Mahendra Kadia, Kayleigh R Marx, Gautam Borthakur, J Michael Savoy, Naveen Pemmaraju, Adam J DiPippo, Naval G Daver, Serena M Chew, Koiji Sasaki, Ghayas C Issa, Nicholas James Short, Koichi Takahashi, Maro N Ohanian, Jing Ning, Lianchun Xiao, Yesid Alvarado, Dimitrios P Kontoyiannis, Farhad Ravandi, Hagop M Kantarjian, Marina Y Konopleva
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127 (14) (2021)
Imane Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, Naval G Daver, Xuemei Wang, Elias J Jabbour, Zeev Estrov, Courtney D D DiNardo, Naveen Pemmaraju, Alessandra Ferrajoli, Nitin Jain, Sa A Wang, Nadya J Jammal, Gautam Borthakur, Kiran Naqvi, Sarah Pelletier, Sherry Pierce, Michael Andreeff, Guillermo Garcia Manero, Jorge E Cortes, Tapan Mahendra Kadia
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127 (11) (2021)
Nadya J Jammal, Caitlin R Rausch, Tapan M Kadia, Naveen Pemmaraju
Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials. Expert opinion on emerging drugs 25 (4) (2020)
Nadya J Jammal, Yifang Eva Pan, Michael Hurwitz, Rebecca B Abramovitz
Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (3) (2019)